Skip to main content

Crohn's disease

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Crohn's disease article more useful, or one of our other health articles.

Synonyms: regional ileitis, terminal ileitis, regional enteritis or granulomatous enteritis

Continue reading below

What is Crohn's disease?

Crohn's disease is a chronic relapsing inflammatory bowel disease (IBD). It is characterised by a transmural granulomatous inflammation which can affect any part of the gastrointestinal tract, most commonly the ileum, colon or both. Unlike ulcerative colitis, there may be unaffected bowel between areas of active disease (skip lesions). The clinical course is characterised by exacerbations and remission.1

Crohn's disease has several extra-intestinal manifestations, including iritis, arthritis, erythema nodosum and pyoderma gangrenosum.2

How common is Crohn's disease? (Epidemiology) 3

  • The incidence and prevalence of Crohn's disease is increasing worldwide, with a systematic review reporting the highest incidence in Australia (29.3 per 100,000 population), Canada (20.2 per 100,000 population) and northern Europe (10.6 per 100,000).

  • The prevalence in the UK is about 145 per 100,000 population.2

  • Crohn's disease is more likely in those with a strong family history (first-degree relatives).

  • Crohn's disease affects both sexes equally and is associated with excess mortality compared with the general population, with a standardised mortality ratio of 1.38.

  • The onset of Crohn's disease has two age peaks: the first and largest peak occurs between the ages of 15-30 years; the second smaller peak is between 50-70 years. People over the age of 60 contribute to 10-15% of IBD diagnoses, compared to 5-25% made in children or adolescents.4

  • However, Crohn's disease is also rapidly increasingly in children. The vast majority of affected children will need immunosuppressant treatment and around 20% will need treatment with biological agents.5

Risk factors

  • There is a genetic element (15-20% will have an affected family member with IBD; 70% concordance in identical twins).

  • Smoking increases risk three- to four-fold and smokers tend to have more aggressive disease and an earlier postoperative relapse.

  • Other exacerbating factors include intercurrent infections (eg, upper respiratory tract infection (URTI) or enteric infection) and non-steroidal anti-inflammatory drugs (NSAIDs).

Continue reading below

Symptoms of Crohn's disease (presentation) 1 3

  • Symptoms are variable but often include diarrhoea (which may be bloody and become chronic - ie present for more than six weeks), abdominal pain and/or weight loss. Such symptoms should raise the suspicion of Crohn's disease, especially in patients of young age.

  • Typically, there will be periods of acute exacerbation, interspersed with remissions or less active disease.

  • Systemic symptoms of malaise, anorexia, or fever are common.

  • The history should include enquiry about possible extra-intestinal manifestations involving the mouth, skin, eyes and joints and episodes of perianal abscess or anal fissure.

  • Children may present with poor growth, delayed puberty, malnutrition and bone demineralisation.


  • General ill health with signs of weight loss, fluid depletion and anaemia.

  • There may be hypotension, tachycardia and pyrexia during acute exacerbations.

  • Abdominal tenderness or distension, palpable masses.

  • Anal and perianal lesions (pendulous skin tags, abscesses, fistulae) are characteristic.

  • Mouth ulcers.

Extra-intestinal features6

  • Clubbing, erythema nodosum, pyoderma gangrenosum.

  • Conjunctivitis, episcleritis, iritis.

  • Large joint arthritis, sacroiliitis, ankylosing spondylitis.

  • Fatty liver, primary sclerosing cholangitis (rare), cholangiocarcinoma (rare).

  • Granulomata may occur in the skin, epiglottis, mouth, vocal cords, liver, nodes, mesentery, peritoneum, bones, joints, muscle or kidney.

  • Renal stones.

  • Osteomalacia.

  • Malnutrition.

  • Amyloidosis.

Diagnosing Crohn's disease (investigations) 3

  • The diagnosis is confirmed by clinical evaluation and a combination of endoscopic, histological, radiological and biochemical investigations.

  • Initial investigations are FBC, CRP, U&Es, LFTs, stool culture and microscopy. Serum levels of CRP are useful for assessing a patient's risk of relapse. High CRP levels are indicative of active disease or a bacterial complication. CRP levels can be used to guide therapy and follow-up.

  • Faecal calprotectin:

    • Calprotectin is a small calcium-binding protein. The concentration of calprotectin in faeces has been shown to correlate well with the severity of intestinal inflammation.7

    • Faecal calprotectin testing is recommended as an option when considering the differential diagnosis of IBD or irritable bowel syndrome.8

    • A normal faecal calprotection level has a very high negative predictive value for IBD. By contrast, the positive predictive value of levels above the assay reference level (normal defined as <50 µg/g stool) is low, and it is recommended that a higher threshold is used to trigger colonoscopy, which improves the positive predictive value .

    • One study looking at children and teenagers found that a diagnostic strategy of using clinical assessment in combination with a positive faecal calprotectin result increased the specificity to detect IBD and reduced the need for referral to a paediatric gastroenterology centre, with a very low risk of missing cases.9

  • Microbiological testing for infectious diarrhoea including Clostridium difficile toxin is recommended. Additional stool tests may be needed for patients who have travelled abroad. See the separate Traveller's diarrhoea article.

  • For suspected Crohn's disease, ileocolonoscopy and biopsies from the terminal ileum as well as each affected colonic segment, to look for microscopic evidence of Crohn's disease, are first-line procedures to establish the diagnosis.

  • Ileocolonoscopy defines the presence and severity of morphological recurrence and predicts the clinical course, so is recommended in all patients where recurrence is suspected.

  • Although evaluation of the bowel has traditionally included imaging using barium fluoroscopic techniques to assess the portions of the small bowel that are inaccessible to endoscopic visualisation, cross-sectional imaging techniques (CT and MRI) are being increasingly used to assess both mural and extramural manifestations of IBD.10

  • Radionucleotide scanning may be used for patients too ill to undergo colonoscopy or barium studies.

  • Gastroduodenoscopy and biopsy are recommended in patients with upper gastrointestinal symptoms.

  • For perianal disease:

    • Pelvic MRI should be the initial procedure because it is accurate and non-invasive, although it is not needed routinely in simple fistulae.

    • Examination under anaesthetic is considered the gold standard but only in the hands of an experienced surgeon. It may permit concomitant surgery.

    • As the presence of concomitant rectosigmoid inflammation has prognostic and therapeutic relevance, proctosigmoidoscopy is used routinely in the initial evaluation.

  • Laparoscopy may be necessary in selected patients and research into its effectiveness compared to laparotomy is ongoing. It is especially useful where the differential diagnosis of intestinal tuberculosis is being considered, and is also frequently employed in paediatric patients.

Continue reading below

Differential diagnosis11


Various staging systems are in use, principally to assess response to treatment and for research purposes. They all rely on a combination of the patient's history, physical findings and laboratory data. Two in common use are the Crohn's Disease Activity Index (CDAI)13 and the Pediatric Crohn's Disease Activity Index (PCDAI).14

Management of Crohn's disease

  • Prompt referral is indicated for any patient with rectal bleeding and abdominal pain, change in bowel habit, weight loss, or iron-deficiency anaemia. Cancer pathway referral should be strongly considered, as faecal calprotectin is not sensitive enough in the exclusion of advanced colorectal adenoma or colorectal carcinoma. This is especially the case in over-50s - while these symptoms in patients under 50 years are strongly predictive of IBD or colorectal cancer, but generally don't discriminate between the two, IBD is significantly more common in younger age groups.

  • Urgent hospital admission for a patient known to have Crohn's disease is required if:

    • There is severe abdominal pain, especially if there is tenderness on palpation.

    • There is severe diarrhoea (frequency eight or more times per day), with or without rectal bleeding.

    • There is bowel obstruction.

    • The patient has fever and is systemically unwell.

  • If the patient does not require admission, assess disease activity by thorough history and examination and blood tests (FBC, CRP, renal function and electrolytes, LFTs).

National Institute for Health and Care Excellence (NICE) guidance

Inducing remission in Crohn's disease15

  • Monotherapy:

    • Offer monotherapy with a conventional glucocorticosteroid (prednisolone, methylprednisolone or intravenous hydrocortisone) to induce remission in people with a first presentation or a single inflammatory exacerbation of Crohn's disease in a 12-month period.

    • Consider enteral nutrition as an alternative to a conventional glucocorticosteroid to induce remission for children in whom there is concern about growth or side-effects, and young people in whom there is concern about growth.

    • In people with one or more of distal ileal, ileocaecal or right-sided colonic disease, who decline, cannot tolerate or in whom a conventional glucocorticosteroid is contra-indicated, consider budesonide for a first presentation or a single inflammatory exacerbation in a 12-month period. Budesonide is less effective than a conventional glucocorticosteroid but may have fewer side-effects.

    • In people who decline, cannot tolerate or in whom glucocorticosteroid treatment is contra-indicated, consider 5-aminosalicylate (5-ASA) treatment for a first presentation or a single inflammatory exacerbation in a 12-month period. 5-ASA is less effective than a conventional glucocorticosteroid or budesonide but may have fewer side-effects than a conventional glucocorticosteroid.

    • Do not offer budesonide or 5-ASA treatment for severe presentations or exacerbations. Do not offer azathioprine, mercaptopurine or methotrexate as monotherapy to induce remission.

  • Add-on treatment:

    • Consider adding azathioprine or mercaptopurine to a conventional glucocorticosteroid or budesonide to induce remission of Crohn's disease if there are two or more inflammatory exacerbations in a 12-month period, or the glucocorticosteroid dose cannot be tapered.

    • Assess thiopurine methyltransferase (TPMT) activity before offering azathioprine or mercaptopurine. Do not offer azathioprine or mercaptopurine if TPMT activity is deficient (very low or absent). Consider azathioprine or mercaptopurine at a lower dose if TPMT activity is below normal but not deficient.

    • Consider adding methotrexate to a conventional glucocorticosteroid or budesonide to induce remission in people who cannot tolerate azathioprine or mercaptopurine, or in whom TPMT activity is deficient, if there are two or more inflammatory exacerbations in a 12-month period, or the glucocorticosteroid dose cannot be tapered.

    • Infliximab and adalimumab:16

      • Infliximab and adalimumab block the action of the cytokine tumour necrosis factor alpha (TNF-α), which mediates inflammation in Crohn's disease.

      • Infliximab or adalimumab is recommended by NICE for the treatment of severe active Crohn's disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications. Treatment should normally be started with the least expensive drug in this class.

      • Patients starting this treatment should be offered advice about the option of monotherapy with Infliximab and adalimumab or combination therapy with an immunosuppressant.

      • Infliximab is recommended for the treatment of fistulating Crohn's disease that has not responded to conventional therapy (including antibacterials, drainage and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications.

      • Infliximab or adalimumab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter.

      • Treatment should be continued beyond 12 months only if there is evidence of active disease. The need for treatment should then be reviewed at least annually. If the disease relapses after stopping treatment, adalimumab or infliximab can be restarted.

    • Vedolizumab is recommended by NICE as an option for treating moderately to severely active Crohn's disease only if a TNF-α inhibitor has failed or a TNF-α inhibitor cannot be tolerated or is contra-indicated.17

    • Ustekinumab is recommended by NICE as an option for treating moderately to severely active Crohn's disease in patients who have failed to respond adequately to, were intolerant of or have contra-indications to conventional therapy or a TNF‑alpha inhibitor.18

    • Risankizumab is recommended by NICE as an option for previously treated moderately to severely active Crohn's disease if the disease has not responded well enough or lost response to a previous biological treatment, or a previous biological treatment was not tolerated, TNF-alpha inhibitors are not suitable.19

    • Upadacitinib is recommended by NICE as an option for treating moderately to severely active Crohn's disease in adults, if the disease has not responded well enough or lost response to a previous biological treatment or a previous biological treatment was not tolerated or TNF-alpha inhibitors are not suitable.20

Severe active Crohn's disease is defined as very poor general health and one or more symptoms such as weight loss, fever, severe abdominal pain and usually frequent (3-4 or more) diarrhoeal stools daily. People with severe active Crohn's disease may or may not develop new fistulae or have extra-intestinal manifestations of the disease.

Maintaining remission in Crohn's disease

  • When people choose not to receive maintenance treatment, discuss plans for follow-up, including the frequency of follow-up and who they should see to ensure they know which symptoms may suggest a relapse and should prompt a consultation with their healthcare professional (especially unintended weight loss, abdominal pain, diarrhoea, general ill-health).

  • Smoking cessation is very important.

  • Maintenance treatment for those who choose this option:

    • Offer azathioprine or mercaptopurine as monotherapy to maintain remission when previously used with a conventional glucocorticosteroid or budesonide to induce remission. Also consider azathioprine or mercaptopurine to maintain remission in people who have not previously received these drugs (particularly those with adverse prognostic factors such as early age of onset, perianal disease, glucocorticosteroid use at presentation and severe presentations).

    • Consider methotrexate to maintain remission only in people who needed methotrexate to induce remission, or have tried but did not tolerate azathioprine or mercaptopurine for maintenance or have contra-indications to azathioprine or mercaptopurine.

    • Do not offer a conventional glucocorticosteroid or budesonide to maintain remission.

  • Maintaining remission in Crohn's disease after surgery:

    • In patients who have had complete macroscopic resection within the last three months, consider azathioprine in combination with up to three months' postoperative metronidazole.

    • If metronidazole is not tolerated, consider azathioprine alone.

    • The effects of azathioprine and metronidazole should be monitored (including monitoring for the neutropenia for all people on azathioprine).

    • Biologics should not be offered to maintain remission after complete macroscopic resection of ileocolonic Crohn's disease.

    • People who started biologics before May 2019 should continue on treatment until they and their healthcare professional agree that change is appropriate.

    • Budesonide should not be offered to people with ileocolonic Crohn's disease who have had complete macroscopic resection to maintain remission.


  • Crohn's disease limited to the distal ileum:

    • Consider surgery as an alternative to medical treatment early in the course of the disease for people whose disease is limited to the distal ileum.

    • Consider surgery early in the course of the disease or before or early in puberty for children and young people whose disease is limited to the distal ileum and who have growth impairment despite optimal medical treatment and/or refractory disease.

  • Managing strictures: consider balloon dilation particularly in people with a single stricture that is short, straight and accessible by colonoscopy. Ensure that abdominal surgery is available for managing complications or failure of balloon dilation.

Monitoring for osteopenia and assessing fracture risk
Crohn's disease is a cause of secondary osteoporosis. Consider monitoring for changes in bone mineral density in children and young people with risk factors, such as low BMI, fragility fracture or continued or repeated glucocorticosteroid use. See also the separate Osteoporosis risk assessment and primary prevention article.

Fistulating Crohn's disease21

  • Treatment may not be necessary for simple, asymptomatic perianal fistulas. Metronidazole or ciprofloxacin can improve symptoms of fistulating Crohn's disease but complete healing is rare.

  • Other antibacterials should be given if specifically indicated, such as for sepsis associated with fistulas and perianal disease, and for managing bacterial overgrowth in the small bowel.

  • Fistulas may also require surgical exploration and local drainage.

  • Either azathioprine or mercaptopurine can be used as a second-line treatment for fistulating Crohn's disease, and continued for maintenance.

  • Infliximab can be used for fistulating Crohn's disease refractory to conventional treatments. Adalimumab can be used if there is intolerance to infliximab.

Other treatments

  • Antidiarrhoeals such as loperamide are contra-indicated during episodes of active colitis, as they may cause toxic megacolon. However, they can be prescribed for the control of chronic diarrhoea in patients with stable disease.

  • Bile acid sequestrants such as colestyramine and colestipol may be useful to control secretory diarrhoea in patients with terminal ileal disease causing bile acid malabsorption.

  • Abdominal cramps may be controlled by antispasmodics such as dicycloverine, or hyoscyamine, providing intestinal obstruction has been excluded.

  • All patients with IBD should undergo individual counselling by a dietitian as part of the multidisciplinary approach to improve nutritional therapy and avoid malnutrition and nutrition-related disorders.22

  • There is no 'IBD diet' that can be generally recommended to promote remission in patients with IBD with active disease.22

    • CD exclusion diet (plus partial enteral nutrition) should be considered as an alternative to exclusive enteral nutrition (EN) in paediatric patients with mild to moderate CD to achieve remission.

    • In adult patients, a CD exclusion diet can be considered with or without EN in mild to moderate active CD.

  • Total parenteral nutrition is appropriate adjunctive therapy in complex, fistulating disease.

Treatment of extra-intestinal manifestations

  • Oral Crohn's disease: topical steroids, topical tacrolimus, intralesional steroid injections, enteral nutrition and infliximab may have a role in management but there are no randomised controlled trials.

  • Arthritis and arthropathy: there is some general support for use of sulfasalazine, simple analgesics, local corticosteroid injections and physiotherapy. In axial arthritis, the arguments in favour of intensive physiotherapy, sulfasalazine, methotrexate or infliximab are somewhat stronger.

  • Erythema nodosum: systemic corticosteroids are usually required.

  • Pyoderma gangrenosum: topical and systemic corticosteroids, with the more toxic ciclosporin and tacrolimus reserved for resistant cases. Data support the use of infliximab.

  • Episcleritis: may not require specific treatment but will usually respond to topical corticosteroids.

  • Uveitis is treated with topical and/or systemic corticosteroids.

  • Primary sclerosing cholangitis: responds to ursodeoxycholic acid. Endoscopic retrograde cholangiopancreatography (ERCP) may be used to treat dominant strictures by dilatation and/or stenting.

  • Advanced liver disease may necessitate transplantation.

Complications of Crohn's disease

  • Bowel:

    • Strictures causing subacute or acute obstruction.

    • Fistulae between loops of bowel and other bowel, bladder, vagina, or skin.

    • Perforation, acute dilatation and massive haemorrhage can occur.

    • Crohn's colitis is associated with an increased risk of colorectal carcinoma (CRC). Colonoscopic surveillance should be offered.23

    • Recent studies consistently show a decline in rates of IBD-associated CRC over the past 20 years potentially as a result of improved therapies.24 However, there is still a greater than 2-fold relative risk of CRC in patients with ulcerative colitis or with colonic Crohn’s disease than the background population.

  • Cancer:

    • The lifetime cancer risk of people diagnosed with IBD in childhood is increased.25

    • This risk increase persists into adulthood, and has not fallen since the introduction of modern drug therapies for IBD.

    • However, absolute risks are low, corresponding to one extra case of cancer for every 556 patients with IBD followed for a year, compared with healthy individuals.

  • Osteoporosis (especially with steroid therapy):

    • Weight bearing, isotonic exercise, stopping smoking, avoiding alcohol excess and maintaining adequate dietary calcium are beneficial.

    • Consider assessing for changes in bone mineral density in children who have low BMI, unexpected fracture or high levels of corticosteroid use.15

    • Regular use of bisphosphonates and raloxifene may reduce or prevent further bone loss.

  • Renal disease (secondary to obstruction of the right ureter by ileocaecal disease).

  • Iron, folate and vitamin B12 deficiency.

  • Gallstones and renal stones (usually oxalate) especially when there has been a previous right hemicolectomy.

  • Crohn's disease may cause a delay in both growth and puberty in children.15

  • If Crohn's disease in a pregnant patient is in remission, there is no effect on the prognosis for pregnancy. Women with active disease are more likely to have complications such as spontaneous abortions, miscarriages, stillbirths and exacerbation of the disease.26 27 Treatment of pregnant women with infliximab does not increase the incidence of adverse outcomes.28


  • The natural history and clinical course of IBD is very variable. More than 50% of patients with Crohn's disease need surgery within 10 years of diagnosis.

  • However, 30% of people with Crohn's disease will have a fairly indolent disease course without the need for immunosuppression or surgery.

  • Clinical indicators of a poor prognosis at diagnosis include perianal or stricturing disease, weight loss >5 kg, or the need for steroids.

Further reading and references

  1. Ha F, Khalil H; Crohn's disease: a clinical update. Therap Adv Gastroenterol. 2015 Nov;8(6):352-9. doi: 10.1177/1756283X15592585.
  2. Crohn's disease; NICE CKS, December 2023 (UK access only)
  3. Kalla R, Ventham NT, Satsangi J, et al; Crohn's disease. BMJ. 2014 Nov 19;349:g6670. doi: 10.1136/bmj.g6670.
  4. Nimmons D, Limdi JK; Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):51-65. doi: 10.4292/wjgpt.v7.i1.51.
  5. Kammermeier J et al, BSPGHAN IBD Working Group; Management of Crohn's disease, Archives of Disease in Childhood, 2016
  6. Malik TF, Aurelio DM; Extraintestinal Manifestations of Inflammatory Bowel Disease.
  7. Walsham NE, Sherwood RA; Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016 Jan 28;9:21-9. doi: 10.2147/CEG.S51902. eCollection 2016.
  8. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel; NICE Diagnostics Guidance, October 2013
  9. Van de Vijver E, Schreuder AB, Cnossen WR, et al; Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child. 2012 Dec;97(12):1014-8. doi: 10.1136/archdischild-2011-301206. Epub 2012 Sep 27.
  10. Kilcoyne A, Kaplan JL, Gee MS; Inflammatory bowel disease imaging: Current practice and future directions. World J Gastroenterol. 2016 Jan 21;22(3):917-32. doi: 10.3748/wjg.v22.i3.917.
  11. Ranasinghe IR, Tian C, Hsu R; Crohn Disease.
  12. Teruel C, Garrido E, Mesonero F; Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):78-90. doi: 10.4292/wjgpt.v7.i1.78.
  13. Adult CDAI (Crohn's Disease Activity Index) Calculator; IBD Support Australia, 2024
  14. Pediatric Crohn's Disease Activity Index Calculator; Cincinnati Children's Hospital Medical Center, 2007; online calculator
  15. Crohn’s disease: management; NICE Guidance (May 2019)
  16. Infliximab (review) and adalimumab for the treatment of Crohn's disease; NICE Technology Appraisal Guidance, May 2010
  17. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy; NICE Technology Appraisal Guidance, August 2015
  18. Ustekinumab for moderately to severely active Crohn’s disease after previous treatment; NICE Technology Appraisal Guidance, July 2017
  19. Risankizumab for previously treated moderately to severely active Crohn's disease; NICE Technology appraisal guidance, May 2023
  20. Upadacitinib for previously treated moderately to severely active Crohn’s disease; NICE Technology appraisal guidance, June 2023
  21. British National Formulary (BNF); NICE Evidence Services (UK access only)
  22. Bischoff SC, Bager P, Escher J, et al; ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. Clin Nutr. 2023 Mar;42(3):352-379. doi: 10.1016/j.clnu.2022.12.004. Epub 2023 Jan 13.
  23. Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas; NICE Clinical Guideline (March 2011 - last updated September 2022)
  24. Gordon H, Biancone L, Fiorino G, et al; ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2023 Jun 16;17(6):827-854. doi: 10.1093/ecco-jcc/jjac187.
  25. Olen O, Askling J, Sachs MC, et al; Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ. 2017 Sep 20;358:j3951. doi: 10.1136/bmj.j3951.
  26. Beaulieu DB, Kane S; Inflammatory bowel disease in pregnancy. World J Gastroenterol. 2011 Jun 14;17(22):2696-701.
  27. Naganuma M, Kunisaki R, Yoshimura N, et al; Conception and pregnancy outcome in women with inflammatory bowel disease: A multicentre study from Japan. A J Crohns Colitis. 2011 Aug;5(4):317-23. Epub 2011 Mar 11.
  28. Schnitzler F, Fidder H, Ferrante M, et al; Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011 Sep;17(9):1846-54. doi: 10.1002/ibd.21583. Epub 2011 Jan 6.
  29. Cleynen I, Boucher G, Jostins L, et al; Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1. Epub 2015 Oct 18.

Article history

The information on this page is written and peer reviewed by qualified clinicians.

symptom checker

Feeling unwell?

Assess your symptoms online for free